Sadhana Nitro Chem Ltd. announced that the company has received approval from the Maharashtra Pollution Control Board (MPCB) for consent to establish the production of Para Aminophenol. Further, the company announced the successful transition to commercial production at its Para Aminophenol (pAP) plant, now operating in a continuous mode. Remarkably, this facility is the world's second plant to manufacture pAP from Nitrobenzene.

Producing pAP from Nitrobenzene, as against its manufacturing from Para Nitro Chloro Benzene (PNCB), offers several significant benefits. The PNCB method is marked by substantial effluent production, while the Nitrobenzene approach aligns with green chemistry principles, generating zero effluent. Notably, the PNCB process results in various chlorine-based contaminants, notably Para Chloro Aniline (PCA), a substance facing increasing restrictions due to its detrimental effects.

In contrast, the Nitrobenzene method avoids using any chlorine-based ingredients, ensuring a product free from PCA and other harmful impurities. The company's initial projection slated the plant's commencement for March 2022, but unforeseen regulatory constraints posed an initial delay. Regardless, the plant was effectively brought to life in June 2022, operating in batch mode.

To ensure the plant's stability and product quality, the company conducted over 100 batch runs while transitioning to continuous production mode. The switch from batch to continuous production necessitated meticulous adjustments in vessel alignment, piping, and instrumentation, a process that spanned six months. Upon initiating continuous mode, SNCL immediately achieved success, stabilising the plant and meeting its previously targeted throughput and quality standards.

Before expanding its capacities, SNCL's primary goal was to elevate our quality standards further, enabling it to cater to a broader spectrum of global customers. The company dedicated an additional four months to elevate its product's specifications, aiming to meet the demands of international clientele. These clients often have stringent and varied quality standards, as the product is utilised not only in generic over-the-counter Paracetamol but also in prescription drugs.

SNCL is thrilled to share that its quality enhancements, first achieved in batch manufacturing mode, now surpass the standards set by any of its global competitors, including those from China. This premium grade of pAP is now recognised and approved by global clients. The company has achieved its targeted levels of quality and production throughput.

Further, it is committed to gradually expanding its supply of products to a broad range of clients, including both international and domestic customers. To support this goal, the company has undertaken an effort to expand its production capacity. The company is firmly committed to its goal of becoming the world's leading manufacturer of pAP within a timeframe of less than three years.